China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. has announced that its subsidiary, Jiangzhong Pharmaceutical, has released its financial results for the first half of 2024, reporting an 8.66% increase in net profit attributable to shareholders despite an 8.02% decrease in revenue. The company’s total assets and net assets saw a marginal increase, while net cash flow from operating activities declined by 11.99%. These mixed results highlight the company’s profitability in a challenging period, with an improved net profit margin and basic earnings per share rising to 0.78 RMB.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
